MULTIPLE SCLEROSIS AND LOWER URINARY TRACT DYSFUNCTION. METHODS OF DIAGNOSTICS; TREATMENT AND FOLLOW-UP REQUIREMENTS

Czech version

Authors: G. Varga ^*; D. Pacík
Authors‘ workplace: Urologická klinika FN Brno LF MU Brno ^*
Published in: Urol List 2012; 10(1): 56-62

Overview

Based on data in literature almost 97% patients with multiple sclerosis suffer from lower urinary tract dysfunction. The impairment concerns both filling and emptying bladder function. Multiple sclerosis, among other diseases, is an underlying condition for neurogenic lower urinary dysfunction, which significantly impair patients’ quality of life. Currently there is a lack of any clearly defined criteria for MS patient care, especially in patients with advanced MS.

Key words:
multiple sclerosis, neurogenic urinary tract dysfunction, urinary incontinence

Sources

1. Havrdová E. Roztroušená skleróza míšní. In: Neuroimunologie. Praha: Maxdorf 2001.

2. Landtblom AM, Fazio P, Fredrikson S et al. The first case history of multiple sclerosis: Augustus d'Este (1794-1848). Neurolgical Sciences 2010; 31(1): 29–33.

3. Zachoval R. Mikční dysfunkce u pacientů s roztroušenou sklerózou. In: Krhut J et al. Neurourologie. Praha: Nakladatelství Galén 2005.

4. Bielekova BM, Kadom NM et al. MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 2005, 11(65): 1071.

5. Chard, D, Miller D. Is multiple sclerosis a generalized disease of the central nervous system? An MRI perspective. Curr Opin Neurol 2009; 22(3): 214–218.

6. Rovaris M, Barkhof F, Calabrese M et al. MRI features of benign multiple sclerosis: Toward a new definition of this disease phenotype. Neurology 2009; 72(19): 1693–1701.

7. Koldewijn EL, Hommes OR, Lemmens WA et al. Relationship between lower urinary tract abnormalities and disease related parameters in multiple sclerosis. J Urol 1995, 154(1): 169–173.

8. Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol 1999; 161(3): 743–757.

9. Krogh K, Christensen P. Neurogenic colorectal and pelvic floor dysfunction. Best Pract Res Clin Gastroenterol 2009; 23(4): 531–543.

10. de Seze M, Ruffion A, Dennys P et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007; 13(13): 915–928.

11. Khan F, Pallant JF, Shea TL et al. Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian community cohort. Disabil Rehabil 2009; 31(19): 1567–1576.

12. Borello-France D, Dusi J, O'Leary M et al. Test-retest reliability of the Urge-Urinary Distress Inventory and Female Sexual Function Index in women with multiple sclerosis. Urol Nurs 2008; 28(1): 30–35.

13. DeRidder D, Ost D, Van der AF et al. Conservative bladder management in advanced multiple sclerosis. Mult Scler 2005; 11(6): 694–699.

14. Varga G, Hajný M, Pacík D et al. Korelace urodynamického nálezu a nálezu na magnetické rezonanci u pacientů s dysfunkční mikcí v důsledku sklerózy multiplex. Čes Urol 2007; 11(1): 37.

15. Lemack GE, Frohman E, Ramnarayan P. Women with voiding dysfunction secondary to bladder outlet dyssynergia in the setting of multiple sclerosis do not demonstrate significantly elevated intravesical pressures. Urology 2007; 69(5): 893–897.

16. Stöhrer M, Castro-Diaz D, Chartier-Kastler E et al. EAU Guidelines on Neurogenic Urinary Tract Dysfunction. In: EAU Guidelines.

17. Stohrer M, Goepel M, Kondo A et al. The standardization of terminology in neurogenic lower urinary tract dysfunction with suggestions for diagnostic procedures. Neurourol Urodyn 1999; 18(2): 139–158.

18. Fowler CJ. Bladder dysfunction in multiple sclerosis: causes and treatment. Int. MS Journal. 1996; 1: 4.

19. Hanuš T. A Value of Urodynamic for Patients with Neurogenic Lower Urinary Tract Dysfunctions. Textbook ESU Course Functional Disorders of the Urinary Tract; an update 2001; 21–28.

20. Bruschini H, Almeida FG, Srougi M. Upper and lower urinary tract evaluation of 104 patients with myelomeningocele without adequate urological management. World J Urol 2006; 24(2): 224–228.

21. Lose G, Griffiths D, Hosker G et al. Standardisation of urethral pressure measurement: Report from the Standardisation Sub-Committee of the International Continence Society. Neurourol Urodyn 2002; 21(3): 258–260.

22. van Waalwijk van Doorn E, Anders K, Khullar V et al. Standardisation of ambulatory urodynamic monitoring: Report of the Standardisation Comittee of the Internationla Continence Society for Ambulatory Urodynamic Studies. Neurourol Urodyn 2000; 19(2): 113–125.

23. Giannantoni A, Scivoletto G, Di Stasi SM et al. Urological dysfunctions and upper urinary tract involvement in multiple sclerosis patients. Neurourol Urodyn 1998; 17(2): 89–98.

24. Krhut J, Hradílek P, Mainer K et al. Nové schéma v diagnostice a terapii dysfunkcí dolních močových cest u pacientů s roztroušenou sklerózou. Urologie pro praxi 2005: 209–212.

25. Wyndaele JJ, Kovindha A, Madersbacher H et al. Neurologic Urinary and Faecal Incontinence. In: Incontinence, 4th Edition, Abrams P, Cardozo L, Khoury S, Wein A (eds.) Plymouth: Health Publication Ltd., 2009: 793–960.

26. McClurg D, Ashe RG, Marshall K et al. Comparison of pelvic floormuscle training electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourol Urodyn 2006; 25(4): 337–348.

27. De Ridder D,Vermeulen C, Ketelaer P et al. Pelvic floor rehabilitation in multiple sclerosis. Acta Neurol Belg 1999; 99(1): 61–64.

28. Lucio AC et al. Pelvic Floor Muscle Training in the Treatment of Lower Urinary Tract Dysfunction in women with Multiple Sclerosis. Neurourol Urodyn 2010; 29(8): 1410–1413.

29. McClurg D et al. Neuromuscular Electrical Stimulation and the treatment of Lower Urinary Tract Dysfunction in Multiple Sclerosis – A Double Blind, Placebo Controlled, Randomised Clinical Trial. Neurourol Urodyn 2008; 27(3): 231–237.

30. Fjorback MV, Van Rey FS, Rijkhoff NJ et al. Electrical stimulation of sacral dermatomes in multiple sclerosis patients with neurogenic detrusor overactivity. Neurourol Urodyn 2007; 26(4): 525–530.

31. Baumer T, Lange R, Liepert J et al. Repeated premotor rTMS leads to cumulative plastic changes of motor cortex excitability in humans. Neuroimage 2003; 20(1): 550–560.

32. Centonze D, Petta F, Versace V et al. Effects of motor cortex rTMS on lower urinary tract dysfunc-tion in multiple sclerosis. Mult Scler 2007; 13(2): 269–271.

33. De Ridder D, Van Poppel H, Baert L et al. From time dependent intermittent self-catheterization to volume dependent self-catheterization in multiple sclerosis using the PCI 5000 bladdermanager. Spinal Cord 1997; 35(9): 613–616.

34. Timoney AG, Shaw PJ. Urological outcome in female patiens with spinal cord injury: the effectiveness of intermittent catheterization. Paraplegia 1990; 28(9): 556–563.

35. Jamil F, Williamson M, Ahmed YS et al. Natural-fill urodynamics in chronically catheterized patients with spinalcord injury. BJU Int 1999; 83(4): 396–399.

36. Wall BM, Dmochowski RR, Malecha M et al. Inducible nitric oxide synthase in the bladder of spinal cord injured patients with a chronic indwelling urinary catheter. J Urol 2001; 165(5): 1457–1461.

37. Ozawa H, Uematsu K, Ohmori H et al. [Long-term usefulness and safety of the contemporary balloon catheter]. Zasshi 2005; 96(5): 541–547.

38. Valiquette G, Herbert J, Maede-D’Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 1996; 53(12): 1270–1275.

39. Odeh M, Oliven A. Coma and seizures due to severe hyponatremia and water intoxication in an adult with intranasal desmopressin therapy for nocturnal enuresis. J Clin Pharmacol 2001; 41(5): 582–584.

40. Krhut J et al Výsledky léčby neurogenních dysfunkcí dolních cest močových aplikací botulinum-toxinu do detruzoru. Čes Urol 2007; 11(3): 77–81.

41. De Ridder D, Chandiramani V, Dasgupta P et al. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term follow up. J Urol 1997; 158(6): 2087–2092.

42. Zajicek J, Fox P, Sanders H et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362(9395): 1517–1526.

43. Duran M, Laporte JR, Capella D. News about therapeutic use of cannabis and enclocannabinoid system. Med Clin 2004; 122(10): 390–398.

44. Chartier-Kastler EJ, Ruud Bosch JL, Perrigot M et al. Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refraktory urge incontinence related to detrusor hyperreflexia. J Urol 2000; 164(5): 1476–1480.

45. Hohenfellner M, Pannek J, Botel U et al. Sacral bladder denervation for treatment of detrusor hyperreflexia and autonomic dysreflexia. Urology 2001; 58(1): 28–32.

46. Zachoval R, Piťha J, Medová E et al. Augmentation cystoplasty in patients with multiple sclerosis. Urol Int 2003; 70(1): 21–26.